This is a transformative reverse merger that hands control of the public entity to Slate Medicines. FULC shareholders face massive dilution as Slate's valuation dwarfs Fulcrum's, but receive a pre-closing cash dividend of excess net cash. The combined company will have a new pipeline and ~$245M in fresh capital. Monitor the shareholder vote and HSR clearance timeline. The deal effectively makes FULC a new biotech with Slate's programs.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $3.84entry
- T+1 · 3mo ago +0.78%α +1.46% · $3.87
- T+5 · 3mo ago 0.00%α +1.19% · $3.84
- T+20 · 2mo ago −1.56%α +0.42% · $3.78
- T+60 · 7d ago −3.13%α −0.18% · $3.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fulcrum Therapeutics (FULC) entered into a definitive merger agreement to acquire Slate Medicines in a reverse-merger transaction. Fulcrum will issue shares to Slate stockholders at an exchange ratio based on a $350M company valuation (plus a concurrent $245M PIPE investment), while Fulcrum is valued at $31.3M. The combined company will operate as Slate Medicines, with Slate's management taking control. Fulcrum stockholders will receive a pre-closing cash dividend of excess net cash above $20.3M. The deal requires shareholder approval and HSR clearance, with a February 28, 2027 outside date. This is a transformative event that effectively hands control to Slate, making FULC a new entity with a new pipeline and substantial cash from the PIPE.
Key Financial Metrics
Key Facts
- Fulcrum Therapeutics to acquire Slate Medicines via reverse merger; Slate valued at $350M pre-money, Fulcrum at $31.3M.
- Concurrent $245M PIPE investment from institutional investors at Slate's pre-money valuation.
- Fulcrum stockholders to receive a pre-closing cash dividend of excess net cash above $20.3M target.
- Combined company to be renamed Slate Medicines, with Slate's management and board taking control.
- Fulcrum CEO Alex Sapir and CFO Alan Musso will depart; Slate CEO Gregory Oakes to lead combined entity.
- Fulcrum's existing pipeline (losmapimod) is effectively being wound down; combined entity will focus on Slate's programs.
- Deal requires Fulcrum stockholder approval for share issuance and reverse stock split; HSR waiting period must expire.
- Fulcrum's VP of Finance Greg Tourangeau departed 7 days prior to deal announcement, replaced by CFO Musso.
Financial Impact
Reverse merger values Slate at $350M pre-money plus $245M PIPE = $595M total; Fulcrum valued at $31.3M. Combined entity will have Slate's pipeline and substantial cash from PIPE.
Risk Factors
- Shareholder vote may fail; Fulcrum's 0% analyst bullish consensus suggests potential opposition.
- HSR review could delay or block the transaction.
- Integration risk: Fulcrum's losmapimod program is being wound down; combined entity's pipeline is unproven.
- Pre-closing cash dividend reduces cash available to combined company; net cash at closing must be ≥ $0 after dividend.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-353278 |
| Document: d136791dex104.htm | 0001193125-26-353278 |
| Document: d136791dex105.htm | 0001193125-26-353278 |
Track record
23 reports on FULC
5 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers